Charmacy Pharmaceutical Reports 8.18% Drop in Operating Revenue and 18.72% Decline in Net Profit for H1 2025; EPS Falls by 18.73%

Reuters

Aug 28, 2025

Charmacy Pharmaceutical Reports 8.18% Drop in Operating Revenue and 18.72% Decline in Net Profit for H1 2025; EPS Falls by 18.73%

Charmacy Pharmaceutical Co. Ltd. has announced its unaudited consolidated interim results for the six months ended 30 June 2025. The company reported a decrease in operating revenue, with figures amounting to RMB 2.155 billion, down 8.18% from RMB 2.347 billion in the same period of 2024. Total profit also saw a decline, registering at RMB 32.629 million, a 16.18% decrease compared to RMB 38.928 million in the previous year. Net profit attributable to shareholders of the parent company decreased by 18.72% to RMB 21.739 million from RMB 26.747 million in 2024. Basic and diluted earnings per share were reported at RMB 0.2013, marking an 18.73% decline from RMB 0.2477 in the previous year. The company's core operations remain focused on pharmaceutical distribution and related services, with all operations and revenue generated within the People's Republic of China. No changes in significant accounting policies or estimates were reported for the period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Charmacy Pharmaceutical Co. Ltd. published the original content used to generate this news brief on August 28, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2562276055"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562276055\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562276055?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-28 22:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562276055","market":"us","top_or_hot":-1,"title":"Charmacy Pharmaceutical Reports 8.18% Drop in Operating Revenue and 18.72% Decline in Net Profit for H1 2025; EPS Falls by 18.73%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Charmacy Pharmaceutical Reports 8.18% Drop in Operating Revenue and 18.72% Decline in Net Profit for H1 2025; EPS Falls by 18.73%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Charmacy Pharmaceutical Co. Ltd. has announced its unaudited consolidated interim results for the six months ended 30 June 2025. The company reported a decrease in operating revenue, with figures amounting to RMB 2.155 billion, down 8.18% from RMB 2.347 billion in the same period of 2024. Total profit also saw a decline, registering at RMB 32.629 million, a 16.18% decrease compared to RMB 38.928 million in the previous year. Net profit attributable to shareholders of the parent company decreased by 18.72% to RMB 21.739 million from RMB 26.747 million in 2024. Basic and diluted earnings per share were reported at RMB 0.2013, marking an 18.73% decline from RMB 0.2477 in the previous year. The company's core operations remain focused on pharmaceutical distribution and related services, with all operations and revenue generated within the People's Republic of China. No changes in significant accounting policies or estimates were reported for the period.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Charmacy Pharmaceutical Co. Ltd. published the original content used to generate this news brief on August 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Charmacy Pharmaceutical Reports 8.18% Drop in Operating Revenue and 18.72% Decline in Net Profit for H1 2025; EPS Falls by 18.73%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCharmacy Pharmaceutical Reports 8.18% Drop in Operating Revenue and 18.72% Decline in Net Profit for H1 2025; EPS Falls by 18.73%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-28 22:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Charmacy Pharmaceutical Reports 8.18% Drop in Operating Revenue and 18.72% Decline in Net Profit for H1 2025; EPS Falls by 18.73%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Charmacy Pharmaceutical Co. Ltd. has announced its unaudited consolidated interim results for the six months ended 30 June 2025. The company reported a decrease in operating revenue, with figures amounting to RMB 2.155 billion, down 8.18% from RMB 2.347 billion in the same period of 2024. Total profit also saw a decline, registering at RMB 32.629 million, a 16.18% decrease compared to RMB 38.928 million in the previous year. Net profit attributable to shareholders of the parent company decreased by 18.72% to RMB 21.739 million from RMB 26.747 million in 2024. Basic and diluted earnings per share were reported at RMB 0.2013, marking an 18.73% decline from RMB 0.2477 in the previous year. The company's core operations remain focused on pharmaceutical distribution and related services, with all operations and revenue generated within the People's Republic of China. No changes in significant accounting policies or estimates were reported for the period.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Charmacy Pharmaceutical Co. Ltd. published the original content used to generate this news brief on August 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02289","symbol_name":"创美药业","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250828:nNDL7vmltC:1","article_id":"2562276055","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562276055","pubTimestamp":1756390892,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Charmacy Pharmaceutical Reports 8.18% Drop in Operating Revenue and 18.72% Decline in Net Profit for H1 2025; EPS Falls by 18.73%. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Charmacy Pharmaceutical Co. Ltd. published the original content used to generate this news brief on August 28, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate","earning"],"viewcount":null,"language":"en","relate_stocks":{"02289":"创美药业"},"translate_title":"Charmacy Pharmaceutical报告2025年上半年营业收入下降8.18%，净利润下降18.72%；每股收益下降18.73%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02289":0.9},"content_text":"Charmacy Pharmaceutical Reports 8.18% Drop in Operating Revenue and 18.72% Decline in Net Profit for H1 2025; EPS Falls by 18.73%\n    \n\n        Charmacy Pharmaceutical Co. Ltd. has announced its unaudited consolidated interim results for the six months ended 30 June 2025. The company reported a decrease in operating revenue, with figures amounting to RMB 2.155 billion, down 8.18% from RMB 2.347 billion in the same period of 2024. Total profit also saw a decline, registering at RMB 32.629 million, a 16.18% decrease compared to RMB 38.928 million in the previous year. Net profit attributable to shareholders of the parent company decreased by 18.72% to RMB 21.739 million from RMB 26.747 million in 2024. Basic and diluted earnings per share were reported at RMB 0.2013, marking an 18.73% decline from RMB 0.2477 in the previous year. The company's core operations remain focused on pharmaceutical distribution and related services, with all operations and revenue generated within the People's Republic of China. No changes in significant accounting policies or estimates were reported for the period.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Charmacy Pharmaceutical Co. Ltd. published the original content used to generate this news brief on August 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,event,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}